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PREFACE 
This thesis is divided into two separate sections. Section I 
describes the effect of the mitogenic lectins, Concanavalin A and Lens 
culinaris agglutinin, on the immune response of pigs to a pseudorabies 
subunit vaccine. Section II describes the effect of pseudorabies virus 
immune serum on the immune response of pigs to a pseudorabies subunit 
vaccine. Each section is presented separately and consists of the 
following subsections; abstract, introduction, materials and methods, 
results, discussion, and bibliography. A review of the literature 
concerning pseudorabies virus, vaccines, and potential adjuvants of 
vaccines precedes these sections. A supplemental literature citation 
pertaining to this review follows section II. 
I 
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GENERAL INTRODUcrION 
The principal method of control of pseudorabies is vaccination. 
Several effective attenuated and inactivated vaccines have been developed 
over the years. However, these vaccines do not prevent infection by 
pseudorabies virus (PRV), the establishment of a latent infection, or 
subsequent recrudescence of the virus in latently infected pigs. 
Further11Dre, infected vaccinated pigs cannot be serologically 
differentiated from non-infected vaccinated pigs, since current vaccines 
contain all viral epitopes. Consequently, pigs that are vaccinated with 
currently available vaccines must be considered potential carriers of the 
virus. Subunit vaccines, a new generation of inactivated vaccines, 
contain a limited number of the total viral epitopes. Therefore, virus 
infected vaccinated pigs, that have antibody to all viral epitopes, can 
be serologically differentiated from non-infected vaccinated pigs. This 
ability would facilitate PRV control programs and could ultimately lead 
to the eradication of PRV from the swine population. 
A disadvantage of subunit vaccines is their cost of production. In 
addition, some viral subunits may not be as immunogenic in their free 
form as they are when they exist as an integral part of the virus. It 
may be possible to overcome these disadvantages by developing ways to 
enhance the immune response of pigs to the subunit vaccines. In the 
following study, the lectins, Concanavalin A and Lens culinaris 
agglutinin, and PRV immune serum were evaluated as immunopotentiating 
agents of a PRV subunit vaccine in pigs. 
3 
LITERATURE REVIEW 
Introduction 
Pseudorabies (Aujeszky's disease) j.s an economically significant 
disease of swine caused by a herpesvirus.36 The virus is found 
worldwide.37 Pseudorabies virus (PRV) causes fatal infections in swine, 
cattle, dogs, cats, and other mammals. 3 • 37 Man is apparently refractive 
to PRV infection, although a few suspect cases have been reported in 
Europe.113 The incidence of pseudorabies has been increasing in the 
United States38 • 112 and throughout the world114 during the past decade 
and is rapidly reaching endemic proportions. A national survey of sera 
from hogs slaug~tered in 1974 indicated that 0.56% were positive for 
antibodies to PRv.27 Similar surveys revealed that the incidence of PRV 
infection in pigs rose to 3.73% in 1978 and to 8.39% in 1981. 103 The 
economic losses due to pseudorabies in 1981 were conservatively estimated 
to cost the Iowa swine industry $33.9 million.8 A 1985 study on the cost 
of pseudorabies to the Iowa swine industry estimated the annual cost of 
the disease to be $107 to $117 million if losses due to reduced sales of 
breeding stock are included. 40 
Vaccines have been extensively used to control the disease. A 
significant disadvantage of the traditional vaccine is that it is not 
possible to determine whether or not a vaccinated pig is a carrier of the 
virus. In 1984, Platt described a PRV subunit vaccine that was produced 
by extracting viral glycoproteins from the merrbranes of virus infected 
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cells.79 The subunit vaccine is unique because it allows- the serological 
differentiation of infected vaccinated pigs from non-infected vaccinated 
pigs. The cost of producing the vaccine on a commercial basis is 
relatively high. The unit cost of the vaccine could be reduced if a 
smaller dose of antigen could be used. One means of accomplishing this 
goal would be to enhance the immune response of pigs to the vaccine 
antigen. Both lectins and immune complexes could be potential 
immunomodulating agents. The following review will focus on the virus, 
the disease that it causes, methods of control, and the use of lectins 
and immune serum as immunopotentiating agents. 
~seudorabies Virus 
The virus 
Pseudorabies virus, also known as Herpesvirus suis2• 107 or Suid 
herpesvirus type 189 , belongs to the family Herpesviridae. The virus has 
been placed in the subfamily alpha~herpesvirinae based on its wide host 
range, short replication cycle, ability to cause rapid cell death, and 
ability to establish latent infections.91• l04 The virulence of the 
virus is correlated to thyrnidine-kinase activity. 52• 53 The virus 
contains double stranded DNA which is surrounded by an icosahedral capsid 
that contains 162 capsomeres. The size of the capsid ranges from 110 to 
230 nm in diameter. 31 The capsid in turn is surrounded by a glycoprotein 
rich envelope that is derived from nuclear and possibly cytoplasmic 
membranes of infected cells.7' 22 
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A minimum of 20 viral envelope proteins have been described. 41 • 79 , 
lOO Eight of these proteins are glycosylated. 41 • 76 • 79 • ioo Four of 
these glycoproteins are highly sulfated, major structural components with 
molecular weights of 125K, 98K, 74K 1 and 58K. 30• 41 The 125K, 74K, and 
58K glycoproteins are covalently linked by disulfide bridges.41 These 
three proteins also share extensive amino acid sequence homology and 
probably originate from a single precursor protein.41 Three minor 
glycoproteins with molecular weights of l30K, 98K, and 62K are 
noncovalently linked to a llSK nonglycosylated protein.41 All seven 
glycoproteins are exposed on the surface of the intact virion. 
Monoclonal antibody studies by Hamp! et al. suggest that the major 98K 
glycoprotein is responsible for inducing serum-virus neutralizing 
antibody. 70 However, Wathen et al. cited evidence that the 58K 
glycoprotein also plays a role in inducing serum-virus neutralizing 
antibody. 113 
A non-structural 90K glycoprotein has also been described by Kaplan 
and Ben-Porat. 50 This protein is sulfated to a greater extent than the 
other major proteins and is excreted from infected cells into the culture 
media. Erickson ang Kaplan proposed that the 90K protein plays a role in 
forming the intracellular matrix that is apparently involved in the 
asserrbly of PRY virions. 30 This protein may be involved in protecting 
the virus from the immune response of the host by promoting cell fusion 20 
or reacting with circulating antibody. 67 A similiar and possibly 
identical protein has been described by Platt et al. who used it as a 
diagnostic antigen to identify virus infected subunit vaccinated pigs.80 
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The disease 
Pseudorabies was ·originally called Aujeszky's disease in honor of 
Aladar Aujeszky, who first described the disease in cattle and 
demonstrated the filterable nature of the agent in 1902. 3 ' 60 As cited 
by Hurst, Marek named the disease infectious bulbar paralysis in 1904 as 
a result of experimental studies in rabbits in which the medulla 
oblongata was affected.48 Sabin noted that Nicolic proposed the name 
pseudorabies in 1932 in the mistaken belief that PRV was a variant of the 
rabies virus.93 Subsequently, Shope demonstrated through serological 
techniques that the cattle disease described by Aujeszky and Nicolic was 
identical to the cattle disease known as 'Mad Itch' in Iowa. 96 Shope 
also demonstrated that the virus causing 'Mad Itch' produced clinical 
disease in swine, which are now recognized as the natural host of PRv. 97 
Clinically, PRV is most severe in pigs under three months of age. 19 • 
47, 94 The predominant manifestations of the disease in this age group 
are central nervous system dysfunction and respiratory system 
involvement. Neurological signs range from slight depression to severe 
disorientation which is frequently followed by convulsions and 
respiratory failure. 34• 36 Newborn piglets often die within 48 hours 
after developing respiratory signs. Older pigs are generally 
inapparently infected, although fatal infections can occur. Typical 
signs in swine, three months or older, include; inappetence, 
listlessness, lassitude, and prostration often accompanied with paddling 
of the extremities. 36 The virus can also cause fetal death and 
resorption during the first trimester of pregnancy. Abortions, 
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stillbirths, and mummified fetuses are common during the last two 
trimesters. 371 47 
Methods of control 
Several factors must be considered in order to successfully control 
PRV. These factors include: shedding and subsequent transmission between 
animals, virus survival in the environment, and latency. Pseudorabies 
virus is spread between pigs primarily by nasal aerosols and fomites. 241 
26 Rabbits, mice, and rats are not thought to play an important role in 
the natural transmission of the disease. 62 Virion survival in the 
environment was found to be dependent on pH level and temperature. 
Davies and Beran demonstrated that an initial inoculum of 107 PFU of PRV 
remained infectious for 10 days at 37 C to 120 days at 4 C at optimum pH 
levels of 6 to a. 24 The virus is sensitive to repeated freezing and 
thawing, drying, and ultraviolet light. 24 Pigs that recover from the 
disease are frequently latently infected with the virus. 9 ' 90 These pigs 
play a· major role in the epidemiology of the disease by periodically 
shedding virus following periods of stress, such as farrowing, 23 
starvation, fighting, bacterial infection36 • 63 or treatment with 
immunosuppressive agents such as dexamethasone.74, 104 
There are two general approaches currently being used to control 
pseudorabies: elimination of PRV from infected herds through specific 
management programs. and vaccination to prevent clinical disease, while 
accepting the. presence of the virus. 
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Management programs The management programs used to date have 
been throughly described by Thawley et a1. 103 These programs include: 
test and removal, offspring segregation, and depopulation-repepulation. 
Test and removal programs involve the serological testing of all pigs in 
a herd every 30 days for six months. All seropositive pigs are 
systematically culled from the herd. This program does not require 
separate confinement quarters and is easily administered. Disadvantages 
of this program are that it does not allow for the salvaging of valuable 
genetic lines and the frequent serological testing required is expensive. 
Offspring segregation programs involve the removal and isolation of 
seronegative weanling pigs from the infected herd. The isolated pigs are 
monitored for PRV antibodies for at least 60 days. If the pigs remain 
seronegative, they are retained and used as breeding stock for a new 
herd. The main advantage of this method is that it permits the salvaging 
of valuable genetic lines. A disadvantage is that the weanling pigs may 
be latently infected with PRV in utero68 • l09 or pre-weaning,5' 89 show 
no clinical signs, and remain seronegative until recrudesence of the 
virus.110 A modification of the offspring segregation method involves 
transferring enbryos from selected infected sows to PRV free sows.12 
Recently, offspring segregation has been combined with controlled 
vaccination. 56 In this program, seropositive pigs are removed from the 
herd. The remaining seronegative pigs are vaccinated with a killed 
vaccine. The first set of offspring that are produced are segregated and 
monitored for PRV antibody. If the segregated pigs remain seronegative 
for 60 days, they are used for the foundation of a new breeding herd. 
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The use of vaccine in the offspring segregation program has increased 
success rates.56 
Depopulation-repopulation programs involve the complete removal of 
all swine from the contaminated premises, which are subsequently cleaned, 
disinfected, and left vacant for a minimum of 30 days. Pseudorabies free 
pigs are used to repopulate the premises. These pigs are monitored for 
at least 30 days and if they remain seronegative, the herd is considered 
to be PRV free. This method is expensive in terms of financial loss due 
to disrupted production and the loss of valuable genetic lines. 
Vaccination Traditionally, two types of vaccines have been used 
for PRV: the modified live or attenuated vaccine and the inactivated or 
killed vaccine. The primary advantage of an attenuated vaccine is that 
the virus multiplies within the host and generates its own antigenic 
mass. Consequently, the immune response of the host is stimulated in 
such a manner that a more competent and longer lasting immunity is 
established than that induced by inactivated vaccines. 44 
The use of an attenuated virus vaccine has two distinct 
disadvantages. First, the use of such vaccines perpetuates the pres~nce 
of the virus in the swine population. Secondly, the attenuated virus has 
the potential of reverting to a virulent form. 5 In addition, vaccines 
that are attenuated for one species of animals may still be virulent for 
another species.105 For example, the BUI< strain of PRV is attenuated 
with respect to pigs but is virulent for sheep.109 Currently, three PRV 
attenuated vaccines are available. Norden Laboratories, Lincoln, NE, 
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markets the attenuated BUK strain104 originally developed by zuffa and 
Polak.115 Tech American corporation, Omaha, NE, markets the BUK strain 
that has been further attenuated by deleting the TK gene. 102 Bioceutic 
corporation, Kansas City, MO, markets the Bartha K strain which was first 
described by Kojnok and Bartha in 1962.66 
The principal advantage of inactivated vaccines is their safety. 
Reversion of virus to a virulent form cannot occur and the vaccine can be 
used safely in a wider range of animals. In addition, killed vaccines 
.can be prepared from virulent strains of PRY that may have antigenic 
epitopes not present in attenuated viruses. The primary disadvantage of 
inactivated vaccines is that they require a relatively large antigenic 
mass for immunization. 18 • 39 Also, multiple doses are usually required 
to produce effective immunity. Currently, inactivated vaccines are 
produced by Norden Laboratories, Lincoln, NE, 70 and Salsbury 
Laboratories, Charles City, IA.5l 
Although both attenuated and inactivated vaccines prevent or reduce 
the severity of clinical disease, they do not prevent superinfection of 
pigs with virulent PRY and subsequent virus shedding.5' 82 For example, 
Maes, et al. demonstrated that virulent virus was shed without clinical 
signs in vaccinated pigs for seven to ten days post infection. 63 
Consequently, all vaccinated pigs must be considered potential carriers 
of the virus. Furthermore, serological differentiation of.virus infected 
vaccinated pigs from non-infected vaccinated pigs is not possible because 
current vaccines contain all the antigenic components of the virus. It 
is for this reason that subunit vaccines have attracted considerable 
attention. 
• 
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Subunit vaccines represent a new generation of inactivated virus 
vaccines that contain a limited number of the antigenic components of the 
whole virus.54 They are inherently safe due to their lack of nucleic 
acids18 and may be less toxic than the whole virion preparation. 92 
Subunit vaccines of enveloped viruses consist of major structural 
glycoproteins, that are usually involved in cell attachment and/or 
penetration,33 and are capable of inducing an immune response in the 
host. 20 Antibcdies developed against these glycoproteins inhibit virus 
adsorbtion and penetration, which limits the course of infection and its 
severity in the host. 15 The limited antigenic composition of subunit 
vaccines makes them ideal for use in control programs because virus 
infected vaccinates can be identified by serologically testing for 
a~tibcdy to non-vaccine viral antigen. 
Subunit vaccines can be prepared by several methods. These methods 
include: extracting specific viral proteins from intact virions64 or from 
virus infected cells,80• 88 • 108 synthesizing specific viral peptides,14 
and recombinant techniques.14• 77 • 86 To date all published accounts of 
PRV subunit vaccine development have dealt with extracted glycoproteins. 
The extraction of virus proteins from in vitro infected cells yields 
larger quantities than extraction· from the virion. 78 The extraction 
methods used for this purpose were originally developed for purifying 
cell-bcund receptors and transplantation antigens. 21 • 42 • 61 These 
methods involved the use of non-ionic detergents, Nonidet P-40 or Triton 
X-100 • 
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One of the first evaluations of PRV glycoprotein extracts was done 
by Rock and Reed in 1980.88 These investigators were able to protect 
mice f~om lethal PRV challenge by immunizing them with a preparation 
prepared by solubilizing the membrane~ of virus infected cells with 
Triton X-100. Turner et al. were also able to induce protection by 
immunizing mice with membranes of infected cells solubilized with Nonidet 
P-40.108 Maes and Schutz reported that NP-40 extracted PRV glycoproteins 
induced significantly higher serum-virus neutralizing antibody titers 
than attenuated or inactivated virus vaccines. 64 Subsequently, Platt 
demonstrated that lectin extracted PRV glycoproteins were highly 
immunogenic in the pig.79 Furthermore, pigs that were immunized with the 
lectin-extracted glycoproteins did not develop antibodies to a PRV-
specific early excreted non-structural protein. As a result of this 
finding, Platt et al. used the early protein as a diagnostic antigen to 
differentiate virus infected vaccinated pigs from non-infected vaccinated 
pigs. 81 
Immunopotentiation of Subunit Vaccines 
Edelman noted that non-replicating, purified subunit vaccines are 
likely to be weak immunogens that will require immunopotentiation if they 
are to be effective. 28 Two potential groups of immunopotentiators are 
lectins and antigen specific immune serum. 
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Lectins 
Lectins are a class of proteins that exhibit specific carbohydrate 
binding specificities59 that have been compared to the reaction of 
antibody with antigen. 98 The majority of lectins have been isolated from 
plants58 although lectins of mammalian origin are also known.13 Lectins 
were first discovered to induce mitogenic activity in lymphocytes by 
Nowell in 1960.73 Subsequently, lectins were used to quantitate and 
evaluate the cell-mediated immune system of mammalian species, including 
pigs, by lymphocyte.blastogenesis.75 • 95 • 111 Most lectins have been 
found to have mitogenic activity and Sharon believes that all lectins may 
prove mitogenic if tested in suitable systems. 95 Coulson and Chambers 
suggested that lectins "bypass" the requirement for antigenic recognition 
and induce cells to undergo immunological activation.17 Two lectins that 
may be particularly useful as immunopotentiators·include Concanavalin A 
(ConA) and Lens culinarius agglutinin (LCA). 
Concanavalin A was purified by Sumner and Howell in 1936.lOl It was 
the first lectin purified and is one of the better characterized T 
lymphocyte stimulating lectins.lO, 16 • 35 It is composed of dimeric, 
tetrameric, and higher-order forms of identical asymetrical subunits with 
molecular weights of 25.5K. 49 The carbohydrate binding sites of ConA are 
specific for alpha-D-mannoside-like residues of glycoproteins. 83 
Prolonged exposure of lymphocytes to ConA is necessary for the induction 
of mitosis and blast transformation. 1• 61 72 This induction may be 
reversed by exposing lymphocytes to competing saccharides72, 84 or 
antibody to ConA.71 
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In vitro studies have demonstrated that lymphocytes transformed' by 
ConA release various lymphokines, including: gamma-interferon, 
granulocyte-macrophage colony stimulating factor, interleukin-2, 
macrophage cytotoxicity factor, and macrophage migration inhibition 
factor.11, 65, 87 other in vitro studies have demonstrated that ConA 
mediates the maturation of B cells by facilitating the focusing of helper 
T cells on the surface of responding B cells.85 
Lens culinarius agglutinin was first described by Landsteiner and 
Raubitschek in 1908,SS and purified by Howard and Sage in 1969.45 It 
consists of two subunits, 461 106 that have similiar structure and 
properties to ConA.lO, 111 The molecular weight of each subunit is 
49K. 106 The binding affinity of LCA is 50 times lower than the binding 
affinity of ConA for the same sugar residues. 99 
The in vivo effects of lectins on the immune response of the host to 
specific immunogens is not well characterized. Egan et al. demonstrated 
that 500 ug of ConA suppressed the humoral immune response in mice to 
sheep red blood cells (RBC) when given at the same time and route.29 
However, if the ConA was given two days prior to the first injection of 
sheep RBC, there was an apparent enhancement of the immune response to a 
second injection of sheep RBC given 7 to 21 days later.29 Barry and 
Hinrichs showed that ConA exerted a positive effect on the immune system 
of mice by enhancing the adoptive transfer of resistance to L. 
monocytogenes. 4 Naspitz and Richter extensively reviewed the in vivo 
effect of phytohemagglutinin and found that while some authors detected 
an immunosuppressive effect, others did not.69 
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Immune serum 
Henry and Jerne demonstrated that 19s anti-sheep RBC antibodies 
given IV one to two hours prior to sheep RBC enhanced the primary immune 
response of mice to the sheep RBC 15 fold. 43 In contrast, the same 
procedure using the 7s antibodies suppressed the immune response. 43 The 
findings of Henry and Jerne were verified by Dennert et al., who were 
abie to enhance the specific antibody response of mice to sheep RBC by 
giving 19s antibody prior to or in combination with the sheep RBc. 25 
Similiarly, Lehner et al. enhanced the antibody response of mice to sheep 
RBC by pretreating mice with sheep RBC specific monoclonal IgM. 57 
In contrast to the immunopotentiation effect of 19s or IgM antibody 
reported by the above workers, Finkelstein and Uhr reported that antigen 
specific 19s and 7s antibody suppressed the antibody response to a 
bacteriophage. 32 However, this immunosuppression was more pronounced 
with the 7s antibody than the 19s antibody. 
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SECTION I. 
THE EFFECT OF THE MITOGENIC LECTINS, CONCANAVALIN A AND LENS CULINARIS 
AGGLUTININ, ON THE IMMUNE RESPONSE OF PIGS TO A PSEUDORABIES SUBUNIT 
VACCINE 
17 
ABSTRACT 
The effect of the lectins, Concanavalin A (ConA) and Lens culinaris 
agglutinin (LCA), on the immune response of pigs to pseudorabies virus 
(PRV) subunit vaccine was evaluated utilizing 118 pigs. Neither lectin 
enhanced the immune response of the pigs to the subunit vaccine. In 
fact, both lectins appear to have had a slight immunosuppressive effect, 
ConA more so than the LCA. 
The PRV subunit vaccine consisted of 15 ug of viral glycoproteins 
and 150 ug of the respective lectin prepared with or without Freund's 
incomplete adjuvant. Two inoculations were given subcutaneously, three 
weeks apart. Subsequently, the pigs were challenged with 107•3 PFU of 
virulent PRV. The immune response of the pigs was determined by the 
development of serum-virus neutralizing (SN) antibody. In addition, the 
cell-mediated immune response was assessed by a lymphocyte blastogenesis 
assay in the adjuvanted subunit vaccine treatments. Further11Dre, the 
clinical response of the pigs to PRV challenge was ascertained by 
survival rates, weight gain responses, and virus shedding patterns. The 
PRV infection was most evident during days 4 through 8 post-virus 
challenge (pc). 
The slopes of the development of the SN antibody ranged from 0.082 
to 0.122 log 2-day-
1 , with no statistically significant differences being 
observed. Overall mean virus stimulation indexes for the post-challenge 
lymphocyte blastogenesis assay were 2.77, 2.65, and 1.91 for the lectin-
free, LCA, and ConA treatments, respectively. No differences were 
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observed between the mean weight gain responses of the treatments. The 
mean weight gain responses for the adjuvanted lectin-free, LCA, and ConA 
treatments were 0.440, 0.298, and 0.297 Kg-day-l for the days 4 to 8 pc 
time period. The slopes of the virus shedding patterns ranged from 
1 -1 . h -0.249 to -0.357 og10-day , wit no significant differences being 
observed. However, the lectin-free and LCA treated pigs consistently 
shed lower quantities of virus and stopped shedding virus 48 hours before 
the ConA treated pigs. The survival data indicated that 100% of the pigs 
receiving a:djuvanted subunit vaccine, with or without lectin, survived 
the PRV challenge, whiie 72%, 75%, and 70% of the pigs receiving non-
adjuvanted lectin-free, LCA, or ConA subunit vaccine treatments, 
respectively, survived the PRV challenge. 
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INTRODUCTION 
pseudorabies is an economically important disease of swine. 
Estimated losses from reduced weight gains, reduced conception rates, 
abortions, and deaths due to pseudorabies cost the Iowa swine industry 
$33.9 million in i981. 4 In 1985, the cost to the Iowa swine industry, 
including sales restrictions on breeding stock, was estimated to be $107 
to $117 million. 12 Major efforts to control the spread of pseudorabies 
depend on vaccination and management. 30 Vaccination of pigs with 
attenuated or inactivated virus is effective. 19 • 32 However, traditional 
vaccines prevent the free movement of swine because pseudorabies virus 
(PRV) infected vaccinated pigs cannot be differentiated from non-infected 
vaccinated pigs. 21 This disadvantage can be overcome with the use of 
subunit vaccines for PRV which would permit the serological 
identification of virus infect~d pigs by using non-vaccine viral 
components as diagnostic antigen. 23 
In 1984, Platt described an effective PRV subunit vaccine, that 
consisted of viral envelope glycoproteins. 22 The viral glycoproteins 
were extracted by lectin affinity chromatography from detergent 
solubilized membranes of virus infected cells. 21 As little as 16 ug of 
vaccine antigen was shown to induce a protective immune response.22 The 
vaccine was also found to be free of an early non-structural viral 
glycoprotein that was subsequently used as a diagnostic antigen to 
identify PRV infected subunit vaccinated pigs.24 
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Although the subunit vaccine provides protection at relatively low 
dose levels, the extraction method may prove too expensive for conunercial 
production. However, immunopotentiating agents may enhance the immune 
response of pigs to the viral glycoproteins, making it possible to reduce 
the a!lOunt of.. antigen necessary for the subunit vaccine, and consequently 
reduce its cost of production. 
The ability of lectins to induce immunoglobulinll, 20, 26, 27 and 
interleukin-25' 18 production in vitro make them excellent candidates for 
immunopotentiating agents. In vivo studies indicate that lectins may 
either suppress or stimulate the immune response. Egan et al. presented 
evidence that Concanavalin A (ConA) could enhance the antibody response 
of mice to sheep red blood cells. 10 Martin de!lOnstrated that it was 
possible to enhance the cytotoxic T lymphocyte response of mice to tu!lOr 
cells by immunizing with ho!lOlogous tU!lOr cells linked to ConA. 17 
Similiarly, ConA-stimulated murine spleen cells significantly enhanced 
the adoptive transfer of resistance to!:!_ monocytogenes. 2 Concanavalin A 
has been shown to activate porcine lymphocytes in vitro. 31 To date there 
have not been similar in vivo studies in food animals. The following 
study was done to determine if the immunity induced by the PRV subunit 
vaccine described above could be enhanced by incorporating either ConA or 
Lens culinaris agglutinin (LCA) into the vaccine preparation. 
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MATERIALS AND METHODS 
Virus, Cells, Media, and Buffer Solutions 
Pseudorabies virus strain BE was used as the source of vaccine 
antigen and for pig challenge. The virus was originally isolated from a 
dog that died of pseudorabies25 and was subsequently plaque purified 
three times in Madin Darby bovine kidney (MDBK) cells. Prior to its use 
as a source of subunit vaccine antigen, the strain had been passaged a 
maximum of 14 times through MDBK cells and seven times through porcine 
kidney (PK) la cells. To insure that the strain maintained its virulence 
for challenge, it was back passaged once through a pig, reisolated in 
MDBK cells, and P?ssed once in PK la cells. All virus was stored in 
aliquots at -70 C in tissue culture media. 
Porcine kidney la cells were obtained from the Veterinary Medical 
Re~earch Institute (Ames, IA). Madin Darby bovine kidney cells were 
obtained from the National Animal Disease Center (Ames, IA). Both cell 
lines were maintained in this laboratory in excess of 10 years and 
propagated at 37 C in a 5% co2 humidified incubator. Growth medium (GM) 
consisted of Eagle's minimun essential medium with Earle's salts and L-
glutamine (MEM) (Gibco Laboratories, Grand Island, NY) supplemented with 
10% heat inactivated fetal calf serum (FCS). Maintenance medium (MM) was 
GM with 2% FCS. Both GM and MM contained 100 units penicillin, 100 ug 
streptomycin and 3 ug amphotericin B per ml. Medium Ml99 (Ml99) 
containing 25 mM hepes buffer, Earle's salts and L-glutamine (Gibco 
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Laboratories, Grand Island, NY) was supplemented with 15%. FCS, and 
contained 100 units penicillin, and 100 ug streptomycin per ml. Calcium 
and magnesium free Hank's balanced salt solution (HBSS) was supplied by 
Gibco Laboratories (Grand Island, NY). 
Saline G consisted of 1.1 g dextrose, 8.0 g sodium chloride, 1.0 g 
lactalbumin hydrolysate, 1.2 mg phenol red, 400 mg potassium chloride, 
153.3 mg sodium phosphate dibasic, 150 mg potassium phosphate monobasic, 
150 mg magnesium sulfate crystal, and 16 mg calcium chloride crystal in 
deionized water q.s. to one liter. Tris-Tricine (TT) buffer, pH 8.6, 
0.025 M, was supplied by Bio-Rad Laboratories (Richmond, CA). Extraction 
buffer (EB) consisted of TT buffer with 1% Triton-X 100. Acid-citrate 
dextrose (ACD) 2X solution consisted of 8 g citric acid monohydrate, 22 g 
sodium citrate and 25 g dextrose in 500 ml deionized water. Cleaning 
flqid consisted of MEM containing 1% FCS, 10 mM hepes, 100 units 
penicillin, 100 ug streptomycin, and 6 ug amphotericin B per ml. 
Phospate buffered saline (PBS), pH 7.2, consisted of 8.5 g sodium 
chloride, 1.15 g. sodium phosphate dibasic, and 270.8 mg potassium 
phosphate monobasic in deionized water q.s. to one liter. 
Experimental Animals 
Four to eight-week-old pigs were obtained from a secondary specific 
• 
pathogen free herd maintained at the College of Veterinary Medicine (Iowa 
State University, Ames, IA). The pigs were maintained on a Ralston 
Purina (St. Louis, MO) standard grower ration and given free access to 
• 
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feed at least seven days prior to virus challenge so that· all pigs would 
be growing at a maximum rate at the time of virus challenge. 
Subunit Vaccine Preparation 
The PRV subunit vaccine, consisted of 15 ug of viral glycoproteins 
per dose, and was produced as previously described by Platt. 21 Briefly, 
PK la cells were grown in 850cm2 roller bottles and infected with PRV at 
a multiplicity of infection greater than 5.0. This multiplicity of 
infection resulted in more than 95% of the cell monolayer showing 
cytopathic effects by 24 hours post inoculation. At this time, the virus 
infected cells were harvested using sterile glass beads, washed three 
times in MEM, and packed by centrifugation at 1900 X g. The cells were 
subsequently resuspended in EB at a ratio of 3.0 ml buffer to 1.0 ml of 
packed cell volume. 
The cell suspension was sonically disrupted with a Branson Sonifier 
350 (Danbury, CT) equipped witn· a microtip using 20 pulses at a 50% duty 
cycle at an output setting of two. The preparation was then gently 
agitated overnight at ·4 C. Unsolubilized material was removed from the 
preparation by centrifugation at 500 X g for 15 minutes. A second 
centrifugation at 105 X g for 90 minutes, resulted in the formation of 
three distinct layers. These layers consisted of a cloudy upper layer, a 
clear middle layer and a sediment layer which composed roughly 20%, 75% 
and 5% of the total volume, respectively. Lipids were removed from the 
upper cloudy layer by freon extraction. The lipid free upper cloudy 
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layer was then pooled with the clear middle layer. Together these two 
layers represented crude viral antigen (CVA). 
Pseudorabies viral glycoproteins were extracted from CVA by lectin 
affinity chromatography utilizing Lens culinaris agglutinin A and B 
covalently immobilized on agarose beads (E-Y Lab, San Mateo, CA). The 
column was prepared for use by washing with three column volumes of EB 
containing 2.5% mannose followed by 10 column volumes of TT buffer. The 
CVA was loaded onto the column and allowed to adsorb overnight at 4 C. 
Following adsorption, the column was rinsed with five column volumes of 
EB followed by five column volumes of TT buffer to remove free Triton X-
100. The viral glycoproteins were then eluted from the column with four 
column volumes of TT buffer containing 2.5% mannose. The eluant 
containing the viral glycoproteins was simultaneously concentrated five 
to 10-fold and dialyzed against 'IT buffer at 4 C using a Pro-DiMem PA-10 
membrane, with a 10 K mw cutoff, in a negative pressure micro dialysis 
concentrator (Bio-Molecular Dynamics, Beaverton, OR). Protein content 
was determined by the dye binding method described by Bradford. 7 
Virus Assay 
Virus was assayed by the plaque method. 9 Duplicate 250 ul samples 
of 10-fold diluted virus suspensions were added to MDBK cell monolayers 
grown in 24-well tissue culture plates (Costar, Cambridge, MA) and 
incubated at 37 C for 90 minutes. The inoculum was then removed and the 
cell monolayers were rinsed twice with saline G before being overlaid 
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with MM containing 0.8% carboxymethylcellulose. The plates were 
reincubated at 37 C for 48 hours, fixed with PBS containing 6.0% 
formalin, and stained with crystal violet. Virus titer (PEU) was 
expressed as the log10• 
Serum-virus Neutralizing Antibody Test 
Serum-virus neutralizing (SN) antibody titers were determined by a 
microtiter procedure utilizing 96-well flat bottom microtiter plates 
(Costar; cambridge, MA) according to a modification of the microtiter 
method described by Hill et a1. 15 All sera were heat inactivated at 56 c 
for 30 minutes prior to titration. Duplicate two-fold dilutions of test 
sera were made leaving 100 ul of diluted serum in each well. 
Subsequently, 50 ul of saline G, containing 300 PFU of PRY, were added to 
individual wells with the exception that serum control wells received 50 
ul of saline G only. The plates were gently shaken and incubated for one 
hour at 37 C in a 5% co2 humidified incubator. Following incubation, 150 
ul of MEM, containing approximately 105•6 MDBK cells per ml, were added 
to each well and the plates reincubated for 72 hours. Cell monolayers 
were then fixed with PBS containing 6% formalin and stained with crystal 
violet. One titer determination was made for each serum on two separate 
days. The 50% SN endpoints were determined and expressed as the 
geometric mean of the two determinations in log2• 
Serum-virus neutralizing antibody titers for the non-adjuvanted 
lectin experiment were determined by the State Veterinary Diagnostic 
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Laboratory (College of Veterinary Medicine, Iowa State University, Ames, 
IA) using a microtiter technique.15 
Lymphocyte Blastogenesis 
Lymphocytes were harvested aseptically from whole blood essentially 
as described by Boyum. 6 Approximately 8.5 ml of blood were collected 
into a vacutainer tube containing 1.5 ml of ACD. Six ml of the citrated 
blood were gently diluted three-fold in PBS and layered over eight ml of 
Histopaque-1077 (Sigma Diagnostics, St. Louis, MO) contained in a 
siliconized 50 ml glass centrifuge tube. An opaque layer of lymphocytes 
was collected from the surface of the histopaque following centrifugation 
at 400 X g for 30 minutes at 25 c, and washed in 15 ml of HBSS. The 
lymphocytes were pelleted by centrifugation at 250 X g for 10 minutes and 
resuspended in 15 ml of 0.85% ammonium chloride solution for 10 minutes 
to lyse c0ntaminating red blood cells. The lymphocytes were washed a 
·Second time in 15 ml of HBSS and resuspended in one ml of HBSS. The 
lymphocyte suspension was quantified using a Colter counter (Coulter 
Electronic Inc., Hialeah, FL) and standardized to io6•4 lymphocytes per 
ml in Ml99. 
The lymphocyte blastogenesis assay was performed essentially as 
described by Kaeberle and Roth. 16 Parameter treatments were run in 
triplicate in 96 well flat bottom microtiter plates. Individual wells 
received 200 ul of the standardized lymphocyte suspension and 25 ul of 
the parameter treatment solution. Virus and mitogen treatments, 
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consisted of 107 PEU of heat inactivated PRV and 0.625 ug· ConA prepared 
in Ml99, respectively. The control treatment consisted of fresh Ml99 
alone. The plates were incubated four days at 37 C in a 5% co2 
humidified incubator .and then labelled overnight with 0.375 uci of 
methyl-H3-thymidine (Amersham Corp., Arlington Heights, IL) contained in 
25 ul of Ml99. The lymphocytes were harvested onto glass fiber pads. 
Beta emissions were counted for each well and were expressed as counts 
per minute (cpm). Mean cpm were determined for each treatment and 
compared. 
Experimental Design 
Non-adjuvanted lectin experiment 
The effect of lectins on the porcine immune response to the PRV 
subunit vaccine was evaluated by comparing the SN antibody response and 
the post-viral challenge clinical response of pigs vaccinated with: a) 
the viral antigen alone, and b) the viral antigen mixed with 150 ug of 
either LCA or ConA. Pigs were randomly assigned to one of four 
treatments: unvaccinated control pigs that served as sentinels for 
adventitious exposure to PRV, lectin-free vaccinates, vaccinates 
receiving LCA, and vaccinates receiving ConA. Each group consisted of a 
minimum of three pigs and was replicated three to six times. All 
inoculated pigs received two, one ml doses of immunogen subcutaneously 42 
and 21 days prior to intranasal virus challenge with 107•3 PEU of PRV. 
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The SN antibody response was assessed by comparing the mean SN 
antibody titers of the treatment groups during immunization and post-
virus challenge (pc). Serum-virus neutralizing antibody titers were 
measured at weekly intervals during immunization and following virus 
challenge. The mean rate of antibody formation was calculated from SN 
antibody titers determined on days 0 through 14 pc. 
The clinical response was evaluated by comparing survival rates, 
mean weight gain responses, and the virus shedding patterns of the 
treatment groups. Weights were recorded and nasal swabs were collected 
in cleaning fluid for virus assay on days O, 2, 4, 6, 8, 10, 12, 14, and 
21 pc. Mean daily weight gain responses were determined over four time 
periods: days 0 through 4, days 4 through 8, days 8 through 12, and days 
12 through 21 pc. The mean rate of viral clearance was calculated from 
the virus titers of nasal swabs collected on days 4, 6, and 8 pc. 
Adjuvanted lectin ex~riment 
The effect of combining lectins with adjuvanted subunit vaccine was 
also evaluated. Treatment groups consisted of a minimum of three 
randomly assigned pigs. Each treatment was replicated three to four 
times. Vaccine inoculums were identical to those described above with 
the exception that they contained 50% (v/v) Freund's incomplete adjuvant. 
The effect of lectins on the porcine immune response to the subunit 
vaccine was assessed as previously described with the exception that the 
cell-mediated immune (CMI) response was also evaluated. In addition, SN 
antibody titers were also measured on days -4, 4 1 and 10 pc. 
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The CMI response was determined by two methods. First, the CMI 
response of individual pigs to PRV was measured on days -4, O, 4, 7, 10, 
14, and 21 pc by the lymphocyte blastogenesis assay. The mean control, 
virus, and mitogen parameter cpm of the individual samples from a given 
treatment were pooled into pre-challenge (days -4 and 0) and post-
challenge (days 4 through 21 pc) periods. The data were balanced by 
separating the replications that contained the LCA treatment from the 
replications that contained the ConA treatment. overall treatment means 
were then calculated and compared. 
Secondly, the CMI response was evaluated more conservatively by 
determining the number of pigs of each treatment that had a positive CMI 
response during three periods: days -4 and o, days 7 and 10, and days 14 
and 21 pc. Only pigs with a virus stimulation index ~ 2.0, on both days 
of a.period, were considered to have a positive PRV specific CMI response 
for that period. Mean SN antibody titers of the pigs with positive and 
negative CMI responses were calculated and compared to determine if the 
SN antibody response was correlated to the CMI response. 
Data Analysis 
The methods of data analysis used in this study take into account 
the multiple observations from a single individual. Only data collected 
from pigs surviving the virus challenge for each treatment were pooled 
for final analysis of each parameter, with the exception of the CMI data 
where all available data were included. By excluding data from pigs that 
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did not survive the virus challenge, comparisons between the treatments 
were not biased by impending death loss. Each replication was run under 
identical conditions and significant variation between the replications 
was not observed. Therefore, the data from all_ replications were pooled 
for analysis. Treatment means of each parameter were compared by an 
ANOVA procedure using a general linear model. 28 conservative degrees of 
freedom, i.e., one degree of freedom for each pig involved· in the 
comparison minus one, were used in determining the statistical 
significance. 
A Chi-square analysis was used to compare clinical survival data and 
the conservative method of determining PRV specific CMI responses of the 
treatment groups.28 
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RESULTS 
Non-adjuvanted Lectin Experiment 
Serum-virus neutralizing antibody 
The mean SN antibody titers are summarized in Table l and 
represented graphically in Figure l. No statistically significant 
differences were observed between the treatments when their rates of 
antibody formation were compared (Table 2). It is interesting to note 
that the mean SN antibody titer for the ConA treatment was less than the 
mean SN antibody titers for the lectin-free or LCA treatments between 
days 0 and 14 pc. For example, on day 7 pc the mean SN antibody titers 
were 2.15, 1.25, and 0.86 log2 for the lectin-free, LCA, and ConA 
treatments, respectively. The absence of a SN antibody response in the 
unvaccinated control pigs prior to virus challenge, and the absence of an 
anamnestic response pc indicates that all the pigs were free of PRY until 
challenged. 
Clinical response 
Survival The. response of pigs to PRV challenge was most evident 
between days 4 and 8 pc, when most.of the death loss occurred and 
clinical signs of PRY infection were most apparent. The number of pigs 
surviving the PRY challenge for the lectin-free, LCA, and ConA treatments 
were 13 of 18 (72.2%), 9 of 12 (75.0%), and 7 of 10 (70.0%), 
respectively. In contrast, only 9 of 21 (42.9%) unvaccinated control 
pigs survived the PRY challenge. 
Table 1. The effect of lectins on the serum-virus neutralizing antibody response of pigs iim11UI1ized 
with pseudorabies virus subunit vaccine without adjuvant 
Mean serum-virus neutralizing antibody titer .:!:_ SE (log2) by daya 
Treatment Nb -42 -21 -14 -7 0 7 14 21 
Lectin-free 13 0.00 o.oo 0.31 0.23 0.15 2.15 4.15 4.23 
+0.00 +0.00 +0.13 +0.17 +0.10 +0.39 +0.30 +0.39 
Lens culinaris 8 0.00 0.00 0.25 0.13 0.13 1.25 5.25 5.38 
agglutinin +0.00 +0.00 +0.16 +0.13 +0.13 +0.49 +0.45 +0.42 
Concanavalin A 7 0.00 o.oo 0.14 0.14 0.29 0.86 3.86 4.29 
+0.00 +0.00 +0.14 +0.14 +0.29 +0.55 +0.55 +0.36 
Un vaccinated 9 o.oo 0.00 0.11 0.00 0.00 0.77 3.44 4.22 
control +0.00 +0.00 +0.11 +0.00 +0.00 +0.40 +0.34 +0.46 
a Day 0 is the day of virus challenge. 
b N equals total number of pigs surviving virus challenge from all replications. 
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Figure 1. 'l'he effect of lectins on the serum-virus neutralizing antibody response of pigs immunized 
with pseudorabies subunit vaccine without adjuvant. Day 0 is the day of virus challenge. 
Treatment groups include: lectin-free - , N=l3; Lens culinaris agglutinin - - - - , N=B; 
Concanaval in A- - -, N=7: and unvaccinated control- ---, N=9. Points represent the 
mean of all pigs surviving virus challenge from all replications 
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Table 2. The effect of lectins on the rate of antibody formation in pigs 
immunized with pseudorabies virus subunit vaccine without 
adjuvant 
Treatment Na X Slopeb SE 
Lectin-free 14 0.091 0.009 
Lens culinaris 8 0.122 0.009 
agglutinin 
Concanavalin A 7 0.085 0.015 
Unvaccinated 9 0.082 0.008 
control 
~ equals total nurrber of pigs surviving virus challenge from 
all replications. 
bThe rate of antibody formation is represented by the slope of the 
curve described by the equation y=mx + b. Slope (m) was calculated 
by regressing. antibody titer on time, i.e., days O, 7, and 14. Day 
0 is the day of virus challenge. 
Weight gain response The weight gain responses are summarized in 
Table 3. There were no statistically significant differences observed 
between the treatments over the time periods analyzed. The mean weight 
gain response of days 4 to 8 pc, for the lectin-free, LCA, and ConA 
treatments were -0.040, 0.069, and -0.051 Kg-day-1, respectively. In 
contrast, unvaccinated controls lost an average of 0.526 Kg-day-1. 
Following day 8 pc, the weight gain responses of all treatments were 
approximately equal indicating recovery from the virus challenge. 
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Table 3. The effect of lectins on the weight gain response of pigs 
immunized with pseudorabies virus subunit vaccine without 
adjuvant 
Mean weight gain + SE (Kg-day-1) 
Treatment 
Lectin-free 14 
Lens culinaris 8 
agglutinin 
Concanavalin A 7 
Unvaccinated 9 
control 
Dayb 0-4 
0.025 
+0.067 
0.016 
+0.178 
0.082 
+0.219 
-0.011 
+0.172 
Day 4-8 
-0.040 
+0.122 
0.069 
+0.143 
-0.051 
+0.174 
-0.526 
+0.177 
Day 8-12 
0.604 
+o.061 
0.781 
+0.221 
0.666 
+0.150 
0.543 
+0.188 
Day 12-21 
0.634 
+0.063 
0.621 
+0.107 
0.629 
+0.093 
0.450 
+0.104 
~ equals the total number of pigs surviving virus challenge from 
all replications. 
bDay 0-4, 4-8, 8-12, and 12-21 pc are time periods over which the 
weight gain responses were calculated. Day 0 is the day of virus 
challenge. 
Virus shedding patterns The virus shedding patterns are 
summarized in Table 4 and represented graphically in Figure 2. No 
statistically significant differences were observed between treatments 
when the rates of virus clearance, between days 4 and 8 pc, were compared 
(Table 5). The greatest amount of virus was shed from on day 4 pc, at 
which time the mean virus titers of the lectin-free, LCA, ConA, and 
unvaccinated control treatments were 4.62, 4.89, 4.75, and 4.11 log
10
, 
respectively. Virus was recovered from all treatments through day 10 pc. 
All LCA treated vaccinates ceased virus shedding by day 12 pc, while 1 of 
Table 4. The effect of lectins on the clearance of virus from the nasal cavities of pigs immunized 
with pseudorabies virus subunit vaccine without adjuvant 
Mean virus titer + SE (log10> by daya 
Treatment Nb 0 2 4 6 8 10 12 14 21 
Lectin-free 13 0.00 2.78 4.62 3.84 1.19 1.06 0.32 0.02 o.oo 
+0.00 +0.31 +0.16 +0.27 +0.26 +0.47 +0.32 +0.02 +0.00 
Lens culinaris 9 0.00 2.46 4.89 3.48 1.40 0.54 0.00 o.oo o.oo 
agglutinin +0.00 +0.41 +0.29 +0.26 +0.52 +0.24 +0.00 +0.00 +0.00 w 
°' Concanavalin A 7 0.00 3.81 4.75 4.42 1. 76 1.06 0.65 0.22 0.00 
+0.00 +0.39 +0.34 +0.31 +0.77 +0.58 +0.42 +0.19 +0.00 
Unvaccinated 9 0.00 3.32 4.11 3.60 2.88 2.60 0.77 0.03 0.00 
control +0.00 +0.31 +0.35 +0.29 +0.61 +0.63 +0.43 +0.03 +0.00 
a Day 0 is the day of virus challenge. 
b N equals total number of pigs surviving virus challenge from all replications. 
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Figure 2. The effect of lectins on the clearance of virus from the nasal cavities of pigs inmunized 
with pseudorabies subunit vaccine without adjuvant. Day 0 is the day of virus challenge. 
Treatment groups include: lectin-free -- 1 N:l3: Lens culinaris agglutinin - - -, N:8: 
Concanavalin A - - 1 N:7: and unvaccinated control- - -, N:9. Points represent the 
mean of all pigs surviving the virus challenge from all replications 
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Table 5. The effect of lectins on the rate of virus clearance from the 
nasal cavities of pigs immunized with pseudorabies virus 
subunit vaccine without adjuvant 
Treatment Na X Slopeb SE 
Lectin-free 13 -0.286 0.028 
Lens culinaris 9 -0.291 0.052 
agglutinin 
Concanavalin A 7 -0.249 0.076 
Unvaccinated 9 -0.046 0.091 
control 
~ equals total number of pigs surviving virus challenge from 
all replications. 
bThe rate of virus clearance is represented by the slope of the 
.curve described by the equation y=mx + b. Slope (m) was calculated 
by regressing virus titer on time, i.e., days 4 1 6 1 and 8. Day 0 
"is the day of virus challenge. 
13 (7.7%) lectin-free vaccinates, 2 of 7 (28.6%) ConA treated vaccinates, 
and 5 ·of 9 (55.6%) unvaccinated controls were still shedding virus on day 
14 pc. No virus shedding was detected in any surviving pig on day 21 pc. 
Adjuvanted Lectin Experiment 
SerlllTh-virus neutralizing antibody 
The SN antibody titers are summarized in Table 6 and represented 
graphically in Figure 3. No statistically significant differences were 
observed between treatments when the rates of antibody formation were 
compared (Table 7). However, the SN antibody response of ConA treated 
Table 6. The effect of lectins on the serum-virus neutralizing antibody response of pigs immunized 
with pseudorabies virus subunit vaccine with adjuvant 
Mean serum-virus neutralizing antibody titer :±:. SE (log2) 
a brday 
Treatment Nb -42 -21 -14 -7 -4 0 4 7 10 14 21 
Lectin-free 15 0.00 o.oo 0.82 0.97 0.87 0.87 0.82 4.62 5.65 5.75 5.82 
+o.oo +0.00 +0.22 +0.23 +0.25 +0.27 +0.26 +0.42 +0.31 +0.28 +0.25 
Lens culinaris 12 0.00 0.00 0.27 0.54 0.43 0.27 0.33 4.00 5.33 5.71 5.83 
agglutinin +0.00 +0.00 +0.16 +0.24 +0.21 +0.21 +0.22 +0.35 +0.23 +0.28 +0.19 w 
'° 
Concanavalin A 14 0.00 o.oo 0.27 0.29 0.30 0.16 0.05 3.11 4.79 5.43 5.32 
+0.00 +0.00 +0.16 +0.17 +0.14 +0.13 +0.05 +0.28 +0.27 +0.24 +0.25 
Un vaccinated 7 0.00 0.00 0.00 o.oo 0.00 0.00 0.00 0.14 2.68 5.21 5.46 
control +0.00 +0.00 +0.00 +o.oo +0.00 +0.00 +0.00 +0.14 +0.23 +0.26 +0.30 
a Day 0 is the day of virus challenge. 
b N equals total number of pigs surviving virus challenge from all replications. 
7 
a: 
~ 6 
(!J ,,,, r-
z 
6 1/( N 
:::J 1/ . 
c( 
I I I ~- 4 ::> N 
w<.!J ,'/ " z9 3 ,, I (/) -
::> 
1/ a: 
> 2 'I I I ~ 
::> i; a: 1 w Cl) --- -- .......... IX --------......-- -
0 __.. 
-42 -36 -28 -21 -14 -7 0 7 14 21 
DAY PRE- AND POST-VIRUS CHALLENGE 
Figure 3. The effect of lectins on the serum-virus neutralizing antibody response of pigs inununized 
with pseudorabies subunit vaccine with adjuvant. Day 0 is the day of virus challenge. 
Treatment groups include: lectin-free - , N=l5; Lens culinaris agglutinin- - - - , N=l2; 
Concanavalin A-----, N=l4; and unvaccinated. control--, N=7. Points represent the 
mean of all pigs surviving virus challenge from a11 replications 
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Table 7. The effect of lectins on the rate of antibody formation ip pigs 
immunized with pseudorabies virus subunit vaccine containing 
adjuvant 
Treatment X Slopeb SE 
Lectin-free 15 0.099 0.006 
Lens culinaris 12 0.108 0.006 
agglutinin 
Concanavalin A 14 0.104 0.006 
Un vaccinated 7 0.091 0.006 
control 
~ equals total number of pigs surviving virus challenge from 
all replications. 
bThe rate of antibody formation is represented by the slope of the 
curve described by the equation y=mx + b. Slope (m) was calculated 
by regressing antibody titer on time, i.e., days 0 1 4, 7, 101 and 
14. Day 0 is the day of virus challenge. 
vaccinates was consistently less than the SN antibody response of lectin-
free or LCA treatment groups between days 0 and 14 pc. For example, on 
day 7 pc the mean SN antibody titers were 4.62, 4.00, and 3.11 log2 for 
the lectin-free, LCA, and ConA treatments, respectively. Furthermore, 
one week prior to the virus challenge the mean SN antibody titers were 
0.97, 0.54, and 0.29 log2, respectively, suggesting that the ConA reduced 
the porcine immune response to the subunit vaccine. The absence of a SN 
antibody response in the unvaccinated control pigs prior to virus 
challenge, and the absence of an anamnestic response ih these pigs pc 
indicates that all pigs were free of PRV until challenged. 
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Cell-mediated immune response 
The CMI responses of vaccinated pigs treated with LCA and ConA are 
summarized in Tables 8 and 9, respectively. No statistically significant 
differences were observed between the lectin-free and LCA treatments 
during the pre- and post-virus challenge periods (Table 8). The pre-
challenge mean virus counts per minute (cpm) of the lectin-free and LCA 
treatments were 1540.5 and 1105.3, respectively. In contrast a 
statistically significant difference of 524 virus cpm (P<0.01) was 
observed between the lectin-free and ConA treatments during the pre-
challenge period, suggesting that ConA had a suppressive effect on the 
development of the CMI response to PRV (Table 9). No differences were 
observed between the mean virus cpm of lectin-free and lectin treatments 
during the post-challenge period. However, the mean virus cpm of the 
lectin-free and lectin treatments were at least two times greater than 
unvaccinated controls (Tables 8 and 9), indicating that the PRV subunit 
vaccine sensitized lymphocytes to PRV. 
Results of the conservative method of evaluating the effect of the 
lectin treatments on the development of a PRV specific CMI response are 
summarized in Figure 4. Prior to challenge, 3 of 15 (20%) lectin-free 
pigs and 2 of 12 (17%) LCA treated pigs had demonstrated positive CMI 
responses for PRV. None of the 14 ConA treated pigs were CMI positive, 
again suggesting that ConA may be immunosuppressive. By the days 7 and 
10' pc period, the number of positive CMI responders increased to 10 of 15 
(67%) lectin-free pigs, 6 of 12 (50%) LCA treated pigs, and 6 of 14 (46%) 
ConA treated pigs. The number of positive CMI responders during the 
Table 8. The effect of Lens culinaris agglutinin on the cell-mediated immune response of pigs 
immunized with pseudorabies virus subunit vaccine with adjuvant as determined by 
l'{rnphocyte blastogenesis 
Pre-challenge a mean cprnb + SE Post-challengec mean cpm.:!:_ SE 
Treatmentd Treatment 
Pararnetere LF LCA UV LF LCA UV 
Control 922.9 1138.7 1081.8 1432.4 1687.3 1761.7 
+169.8 +311.8 +261.1 +146.9 +265.5 +414.2 
Virus 1540.5 1105.3 770.2 4316.2 4466.7 1697.8 
+207.6 +234.7 +200.3 +608.9 +568.1 +234.9 
Mitogen 25610.3 21829.5 23356.7 42709.7 39357.8 32478.4 
+4295. 7 +5089.9 +5044.6 +5024.4 +6077.5 +6797.2 
a Pre-challenge values are pooled means calculated from data collected on days -4 and O. Day 0 
is the day of virus challenge. 
b Counts per minute. 
c Post-challenge values are pooled means calculated from data collected on days 4 1 7 1 10 1 14, 
and 21 post-virus challenge. 
dLF = lectin-free, N=l2; LCA =Lens culinaris agglutinin, N=l2; UV= unvaccinated control, N=l2 
and 7 pigs at the beginning and end of the virus challenge period. 
eControl = 25 ul Ml99: Virus = 25 ul Ml99 containing 107 PFU heat inactivated PRV: Mitogen = 25 
ul Ml99 containing 0.625 ug ConA. 
.!> w 
Table 9. The effect of Concanavalin A on the cell-mediated immune response of pigs i111Dunized with 
pseudorabies virus subunit vaccine with adjuvant as determined by lymphocyte blastogenesis 
Pre-challenge a mean cpmb + SE Post-challengec mean cpm :t SE 
Treatmentd Treatment 
Parametere LF Con A UV LF Con A UV 
Control 896.0 1133.6 1009.9 1627.6 2150.4 1716.7 
+136.9 +233.4 +198.6 +151.1 +248.5 +361.9 
Virus 1443.5 920.6 865.6 4151.8 4101.0 1822.1 
+174.4 +139.8 +157.6 +510.6 +544.4 +220.8 
Mitogen 32461. 7 29252.3 29901.4 45605.6 43057.6 33679.0 
+4360.3 +4115.7 +4684.6 +4256.8 +5052.6 +6102.6 
a Pre-challenge values are pooled means calculated from data collected on days -4 and o.· Day 0 
is the day of virus challenge. 
b Counts per minute. 
c Post-challenge values are pooled means calculated from data collected from days 4 1 7, 10 1 14, 
and 21 post-virus challenge. 
dLF = lectin~free, N=l2; ConA = Concanavalin A, N=l5; UV = unvaccinated control, N=l2 and 7 
pigs at the beginning and .end of the virus challenge period. 
eControl = 25 ul Ml99; Virus = 25 ul Ml99 containing 107 PFU heat inactivated PRV; Mitogen = 25 
ul Ml99 containing 0.625 ug ConA. 
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Figure 4. The effect of lectins on the cellular immune response of pigs immunized with pseudorabies 
subunit vaccine with adjuvant, A positive response was indicated by a virus stimulation 
index > 2.00 on two consecutive determinations. Day 0 is the day of virus challenge. 
Treatments are; lectin-free ( 0 ) , N=l5; Lens culinaris agglutinin ( ~ ) , N=l2; 
Concanavalin A ( f;:Sj·), N'=l4 ;. and unvaccinated control ( D ) , N=l6, 9, and 7 on days -4 
and O, days 7 and i.O, and days 14 and 21, respectively 
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final period, days 14 and 21 pc, were 5 of 15 (33%), 6 of. 12 (50%), and 5 
of 14 (36%) for the three treatments, respectively. No positive CM! 
responders were detected among the unvaccinated control treatment, pre-
or post-virus challenge. These differences were not significant by chi-
square analysis. 
The SN antibody titers of pigs with positive CM! responses, as 
determined by the conservative method, were compared to the SN antibody 
titers of pigs with negative CM! responses for each of the three periods 
analyzed. The results of these comparisons are summarized in Table 10. 
No significant differences were observed. 
Clinical response 
Survival The survival rates of 15 lectin-free, 12 LCA, and 14 
ConA treated pigs were all 100%. In contrast, only 7 of 16 (43.8%) 
unvaccinated controls survived the virus challenge. 
Weight gain response The weight gain responses are summarized in 
Table 11. No statistically significant differences were observed between 
the treatments. The mean weight gain responses of all treatment groups 
ranged from 0.016 to 0.024 Kg-day-l during first 4 days pc. Weight gains 
increased dramatically between day 4 and 8 pc to 0.440, 0.298 1 and 0.292 
Kg-day-l in the lectin-free, LCA, and ConA treatment groups, 
respectively. In contrast, unvaccinated controls lost an average of 
0.057 Kg-day-l during this period. Although the differences between the 
lectin-free treatment and the lectin treatments were not significant 
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Table 10. Correlation of the serum-virus neutralizing antibody and cell-
mediated immune responses of pigs immunized with adjuvanted 
pseudorabies virus subunit vaccine with and without lectins 
Mean serum-virus neutralizing antibody titer + SE (log2) 
L~ LCA ConA UV 
Timeb 
period CMI+C CMI- CMI+ CMI- CMI+ CMI- CMI+ CMI-
Pre- 1.51 0.70 1.19 0.20 NAd 0.23 NA 0.00 
.challenge +0.54 +0.98 +1.68 +0.28 +0.47 +0.00 
Early post- 5.73 3.95 4.65 4.60 4.46 3.56 NA 1.38 
challenge +0.08 +l.60 +1.02 +0.80 +0.93 +0.92 +0.35 
Late post- 6.42 5.46 6.15 5.38 5.50 5.28 NA 5.34 
challenge +0.40 +l.00 +0.62 +0.82 +0.56· +l.00 +0.70 
aLF = lectin-free, N=l5; LCA = Lens culinaris agglutinin, N=l2; 
ConA = Concanavalin A, N=l4; ~unvaccinated controls, N=l6, 9, 
and 7 pre-challenge, early post-challenge, and late post-challenge, 
respectively. 
b 
Pre-challenge = days -4 and O; Early post-challenge = days 7 and 
10; Late post-challenge = days 14 and 21. Day 0 is the day of 
virus challenge. 
cCMI+ = stimulation index > 2.00 on two days; CMI- = stimulation 
index < 2.00 on at least one day. 
~one available. 
between day 4 and 8 pc, they do suggest that the lectins may be 
immunosuppressive. Following day 8 pc, the weight gain responses of all 
treatments were approximately equal indicating recovery from the virus 
challenge. 
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Table 11. The effect of lectins on the weight gain response of pigs 
immunized with pseudorabies virus subunit vaccine with 
adjuvant 
Mean weight gain ::!:. SE (Kg day-l) 
Treatment Na Da~ 0-4 Day 4-8 Day 8-12 Day 12-21 
Lectin-free 15 0.025 0.440 0.497 0.673 
+0.109 +0.097 +o.097 +0.020 
Lens culinaris 12 0.016 0.298 0.601 0.726 
agglutinin +0.101 +0.162 +0.041 +0.022 
Concanavalin A 14 0.024 0.297 0.560 0.722 
+0.112 +0.035 +0.066 +0.026 
Unvaccinated 7 0.256 -0.057 0.421 0.572 
control +0.071 +0 •. 114 +0.088 +0.061 
~ equals the total number of pigs surviving virus challenge from 
all replications. 
bDay 0-4 1 4-8, 8-12, and 12-21 pc are time periods over which the 
weight gain responses were calculated. Day O is the day of virus 
challenge. 
Virus shedding patterns The virus shedding patterns are 
summarized in Table 12 and represented graphically in Figure 5. No 
statistically significant differences were observed between the 
treatments when the rates of virus clearance, between days 4 and 8 pc, 
were compared (Table 13). The greatest amount of virus was shed on day 4 
pc, at which time the mean virus titers for the lectin-free, LCA, ConA 
treatment groups, and unvaccinated controls were 4.33, 4.78, 4.98, and 
5.57 log10 , respectively. Virus was recovered from all treatments 
through day 8 pc. Lectin-free and LCA treated vaccinates ceased virus 
Table 12. The effect of lectins on the clearance of virus from the nasal cavities of pigs immunized 
with pseudorabi_es virus subunit vaccine with adjuvant 
Mean excreted virus titer + SE (log
10
) by daya 
Treatment 0 2 4 6 8 10 12 14 21 
Lectin-free 15 0.00 3.12 4.33 2.55 0.14 0.00 0.00 o.oo 0.00 
+0.00 +0.43 +0.41 +0.40 +0.08 +0.00 +0.00 +0.00 +0.00 
Lens culinaris 12 o.oo 3.92 4.78 3.11 0.63 0.00 o.oo 0.00 o.oo 
agglutinin +0.00 +0.30 +0.34 +0.54 +0.25 +0.00 +0.00 +0.00 +0.00 
Concanavalin A 14 0.00 4.32 4.98 3.70 0.70 0.19 0.00 0.00 o.oo 
+o.oo +0.29 +0.18 +0.37 +0.29 +0.19 +0.00 +o.oo +0.00 
Unvaccinated 7 o.oo 4.13 5.57 4.64 3.31 1.12 0.65 0.00 0.00 
control +0.00 +0.28 +0.24 +0.45 +0.57 +0.62 +0.44 +o.oo +0.00 
a Day 0 is the day of virus challenge. 
b N equals the total number of pigs surviving virus challenge from all replications. 
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Figure 5. The effect of lectins on the clearance of virus from the nasal cavities of pigs immunized 
with pseudorabies subunit vaccine with adjuvant. Day 0 is the day of virus challenge. 
Treatment groups include: lectin-free --, N=lS; Lens culinaris agglutinin- - - -, N=l2; 
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Table 13. The effect of lectins on the rate of virus clearance of pigs 
immunized with pseudorabies virus subunit vaccine with 
adjuvant 
Treatment X Slopeb SE 
Lectin-free 15 -0.350 0.033 
Lens culinaris 12 -0.346 0.031 
agglutinin 
Concanavalin A 14 -0.357 0.030 
Un vaccinated 7 -0.188 0.054 
control 
~ equals total nllllber of pigs surviving virus challenge from 
all replications. 
bThe rate of virus clearance is represented by the slope of the 
curve described by the equation y=mx + b. Slope (ml was calculated 
by regressing virus titer on time, i.e., days 4, 6, and 8. Day 0 
is the day of virus challenge. 
shedding by day 10 pc. In contrast, 2 of 14 (14.3%) ConA treated 
vaccinates shed virus on day 10 pc, and 3 of 9 (33.3%) surviving 
unvaccinated control pigs were still shedding virus on day 12 pc. 
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DISCUSSION 
The primary objective of this experiment was to determine if the 
incorporation of lectin in a PRV subunit vaccine would enhance the 
porcine immune response to the vaccine. Results of the above experiments 
indicated that neither LCA nor ConA enhanced the immune response of pigs 
to the subunit vaccine. In fact, the data suggest that both lectins may 
have actually been slightly immunosuppressive. For example, although no 
statistically significant differences were observed in the development of 
the SN antibody response between the treatments, the mean SN antibody 
titers of lectin-treated pigs were consistently lower by day than the 
corresponding titers of the lectin-free vaccinates. This trend was 
apparent between days -14 and 7 pc among pigs inoculated with vaccine 
without adjuvant (Table 1) and between days -14 and 10 in pigs inoculated 
with adjuvanted vaccine (Table 3). 
Lectin-treated pigs also appeared to be more severely affected 
' clinically than lectin-free pigs following virus challenge. This effect 
was most apparent between days 4 and 8 pc among treatments receiving 
adjuvanted vaccine. The mean daily weight gain of the lectin-free 
vaccinates was 0.440 Kg-day-l in contrast to 0.298 and 0.297 Kg-day-1 for 
the vaccinates receiving LCA and ConA, respectively (Table 11). A 
similar trend was also evident in the virus shedding patterns of the 
adjuvanted treatments between days 4 and 8 pc. During this period the 
overall mean virus titer shed daily by the lectin-free vaccinates was 
2.34 log2 in contrast to 2.84 and 3.13 log2 of LCA and ConA treated 
vaccinates, respectively (Table 12). 
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Further evidence suggesting that lectins may be immunosuppressive in 
the pig was provided by studies on the CMI response of pigs receiving 
adjuvanted vaccine. Prior tci virus challenge, the mean virus stimulated 
cpm of the lymphocyte blastogenesis assay were greater in the lectin-free 
vaccinates than in vaccinates receiving lectins (Tables 8 and 9). 
However, this difference was only significant when the ConA treatment was 
compared to the lectin-free treatment (p<0.01). This comparison suggests 
that ConA may be more immunosuppressive than LCA. When the CMI data were 
analyzed by the conservative method, a similar effect was observed. 
Prior to virus challenge, none of 14 ConA treated pigs were CMI positive. 
In contrast, 3 of 15 (20%) lectin-free pigs and 2 of 12 (17%) LCA treated 
pigs were CMI positive. 
Although the lectins appeared to be immunosuppressive at the dose 
levels tested, their overall effect on vaccinated pigs was only minor. 
The survival rates of the lectin-free and lectin treated pigs were 
essentially the same and markedly greater than the unvaccinated control 
pigs. Similarly, the weight gains of vaccinates were significantly 
greater (p<0.05) than the weight gains of unvaccinated control pigs 
between days 4 and 8 pc, when the clinical signs of the disease were most 
pronounced. In addition, an anamnestic antibody response was observed in 
the vaccinated pigs after virus challenge that was not observed in the 
unvaccinated controls. Furthermore, PRV specific CMI responses were 
detected in vaccinates, but not in unvaccinated control pigs following 
virus challenge. The overall mean virus stimulation indexes, calculated 
from the post-challenge data summarized in Tables 8 and 9, were 2.77, 
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2.65, and 1.91 for the lectin-free, LCA, and ConA treatments, 
respectively. In contrast, the overall mean virus stimulation index for 
the unvaccinated control treatment was only 1.01. When the <l>II data were 
analyzed by the conservative method, 5 of 15 (33%) lectin-free pigs, 6 of 
12 (50.0%) LCA treated pigs, and 5 of 14 (36%) ConA treated pigs were Cl'II 
positive two weeks after the virus challenge. No <l>II response was 
detected by the conservative method in unvaccinated controls at this 
time. These differences in the immune and clinical responses of 
vaccinated and unvaccinated pigs, indicate that the adjuvanted PRV 
subunit vaccine sensitized the porcine immurie system to PRV in the 
presence or absence of LCA or ConA. 
The slight immunosuppressive effect of lectins observed in this 
study, may have been due to the concentration and time of lectin 
administration. Egan et al. demonstrated that ConA could enhance the 
immune response to an antigen if given three days prior to administration 
of the antigen. In contrast, ConA significantly depressed the antibody 
response of mice to sheep red blood cells if it was given at the same 
time and by the same route. 10 The mechanism by which such 
immunosuppression occurs in vivo has not been clearly defined. The 
normal development of a specific immune response depends on the 
interaction of antigen presenting macrophages and helper T (Th) 
lymphocytes.~ This interaction is facilitated through the binding of 
major histocompatibility complex and antigen specific receptors. As a 
result, interleukin-2 is produced which facilitates the expansion of B 
and T lymphocyte clones. The B lymphocytes further differentiate into 
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antibody producing plasma cells. Some investigators believe that B 
lymphocyte differentiation must be preceded by capping of membrane 
associated immunoglobulin molecules around an immunoglobulin-antigen 
complex. The duration and intensity of the immune response is also 
thought to be limited by suppressor T (Ts) lymphocytes. Consequently, 
any agent that induces Ts lymphocyte .formation, or interferes with the 
expression or mobility of specific. lymphocyte membrane receptors, can be 
expected to suppress the immune response. In vitro studies have 
demonstrated that ConA can stimulate the formation of Ts lymphocytes, 1 as 
well as interfere with the expression,81 14 and the mobility of menbrane 
bo~d immunoglobulin receptors. 13 • 33 
The reduced immune response observed in the lectin treated pigs may 
not have been due to a direct effect of lectins on lymphocytes as 
described above. The antigen dose used in the present study was selected 
because it approached the minimal amount necessary to induce an immune· 
response, 22 and therefore any en.hancement of the immune response of the 
pigs would have been more easily observed. Consequently, the immune 
response of the pigs may have been reduced if the amount of antigen 
available was reduced even slighty by complexing with either of the 
lectins. It is interesting to note that pigs which received ConA 
appeared to have a weaker immune response than pigs that received LCA. 
This difference may have been due to the fact that ConA binds 
glycoprotein 50 times stronger than LCA. 29 
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SECTION II. 
THE EFFECT OF PSEUDORABIES VIRUS IMMUNE SERUM ON THE 
IMMUNE RESPONSE OF PIGS TO A PSEUDORABIES SUBUNIT VACCINE 
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ABSTRACT 
The effects of immune serums on the immune response of pigs to a 
pseudorabies virus (PRV) subunit vaccine were evaluated utilizing 18 
pigs. Fifteen pigs were randomly assigned to three groups, i.e., early 
immune serum, late immune serum, and normal serum. Three.pigs served as 
sentinai controls. Neither the early or late immune sera markedly 
enhanced the immune response of the pigs. However, the early immune 
serum appeared to have had a positive effect as compared to the normal or 
late immune sera. 
Early and late immune serums were collected on days 7 and 21 post-
infection, respectively, from untreated pigs that had been experimentally 
infected with PRV. Normal serum was collected from the same pigs prior 
to.the challenge. The normal serum and early immune serum were negative 
for serum-virus neutralizing (SN) antibody, while the late serum had a SN 
antibody titer of 3.0 log2• The experimental regime consisted of two 
doses of vaccine. For the first dose, five ml volumes of the serums were 
administered with 100 ug of viral glycoproteins sc. A second dose 
containing the viral glycoproteins alone was given two weeks later. 
Three weeks after the second dose of vaccine, ie. day o, the pigs were 
challenged with 107. 3 PFU of virulent PRV. The effects of the treatments 
were assessed by comparing the SN antibody response and the survival 
rates of the pigs post-virus challenge (pc). 
Prior to day 7 pc, the mean SN antibody titers of the treatment 
groups were essentially zero. The mean SN antibody titer of the late 
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immune serum treatment was significantly (p<0.01) depressed on day 7 pc 
as compared to the normal serum and early immune serum treatment groups. 
Mean SN antibody titers on day 7 pc were 3.0o+0.82, 3.00+0.7,and 
l.4o+0.24 log2 for the normal, early, and late immune serum treatments, 
respectively. However, only 2 of 5 (40%) pigs treated with the normal 
immune serum survived through day 7 pc. In contrast, all five pigs of 
the early and late immune serum treatments survived through day 7 pc. 
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INTRODUCTION 
Pseudorabies is an economically important disease of swine.22 
Estimated losses from reduced weight gains, reduced conception rates, 
abortions, and deaths due to pseudorabies cost the Iowa swine industry 
$33.9 million in 1981. 2 In 1985., the cost to the Iowa swine industry was 
estimated to be $107 to $117 million if sales restrictions on 
pseudorabies virus (PRV) infected breeding stock were included. 6 Major 
efforts to control the spread of PRV depend on vaccination and 
management.91 19 vaccination of pigs with attenuated or inactivated 
virus vaccines is effective. 12• 23 However traditional vaccines prevent 
the free movement of swine because PRY infected vaccinated pigs cannot be 
differentiated from non-infected vaccinated pigs. 13 This disadvantage 
can be overcome with the use of subunit vaccines for PRY which would 
permit the serological identification of virus infected pigs by using 
non-vaccine viral components as diagnostic antigen. 15 
In 1984, Platt described an effective PRV subunit vaccine that 
consisted of viral envelope glycoproteins. 14 The viral glycoproteins 
were extracted by lectin affinity chromatography from detergent 
solubilized membranes of virus infected cells.13 As little as 16 ug of 
the viral glycoproteins were shown to induce a protective immune 
response. 14 The subunit vaccine was also found to be free of an early 
non-structural viral glycoprotein that was subsequently used as a 
diagnostic antigert to identify virus infected subunit vaccinated pigs.16 
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Although the viral glycoproteins provide protection at relatively 
low dose levels, the extraction method may prove too expensive for 
commercial production. The vaccine could be made more economical if the 
antigen dose required to induce protection could be reduced. This goal 
might be achievable through the use of immunomodulating agents that would 
enhance the immune response of pigs to the PRY subunit vaccine. 
Several groups of investigators have demonstrated that early immune 
serum given separately or in combination with specific antigen can 
influence the immune response to that antigen.I' 11, 201 21 Henry ahd 
Jerne clearly demonstrated that the primary immune response of mice to 
sheep red blood cells (RBC) was increased 15 fold by pretreating mice 
with 19s (IgM) anti-sheep RBC antibodies. 7 Dennert et al. 5 demonstrated 
the same effect by either pretreating mice with IgM or combining IgM with 
the sheep RBC. Lehner et al. 10 were also able to enhance the antibody 
response of mice to sheep RBC by pretreating with sheep RBC specific 
monoclonal IgM. The following study was done to determine if the immi.lne 
response of pigs could also be enhanced by incorporating immune serum 
with the PRV subunit vaccine. 
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MATERIALS AND METHODS 
Virus, Cells, Media, and Buffer Solutions 
Pseudorabies virus strain BE was used both as the source of vaccine 
antigen and for pig challenge. The virus was originally isolated from a 
dog that died of pseudorabies17 and was subsequently plaque purified 
three times in Madin Darby bovine kidney (MDBK) cells. Prior to its use 
as a source of subunit vaccine antigen, the strain had been passaged a 
maximum of 14 times through MDBK cells and seven times through porcine 
kidney (PK) la cells. To insure that the strain maintained its virulence 
for challenge, it was back passaged once through a pig, reisolated in 
MDBK cells, and passed once in PK la cells. The virus titer was 
determined by a plaque assay method4 and stored in alloquotes of tissue 
culture growth media at -70 C. 
Porcine kidney la cells were obtained from the Veterinary Medical 
Research Institute (Iowa State University, Ames, IA). Madin Darby bovine 
kidney cells were obtained from the National Animal .Disease Center (Ames, 
IA). Both cell lines were maintained in this laboratory in excess of 10 
years and propagated at 37 C in a 5% m2 humidified incubator. Growth 
medium consisted of Eagle's minimun essential medium (MEM) with Earle's 
salts and L-glutamine (Gibco Laboratories, Grand Island, NY) supplemented 
with 10% heat inactivated fetal calf serum and contained 100 units 
penicillin, 100 ug streptomycin and 3 ug amphotericin B per ml. 
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Experimental Animals 
Four to eight-week-old pigs were obtained from a secondary specific 
pathogen free herd maintained at the College of Veterinary Medicine (Iowa 
State University, Ames, IA). The pigs were maintained on a Ralston 
Purina (St. Louis, MO) standard grower ration. 
Serum-virus Neutralizing Antibody 
Duplicate, serum-virus neutralizing (SN) antibody titer 
determinations were performed by the State Veterinary Diagnostic 
Laboratory (College of Veterinary Medicine, Iowa State University, Ames, 
IA), according to a modification of the microtiter method described by 
Hill et al.8 Briefly, two-fold dilutions of heat inactivated test sera 
were made so that 50 ul of diluted serum remained in each well of a 96-
well microtiter plate. Subsequently, 50 u1 of MEM containing 
approximately 300 TCID50 of PRY were added to individual wells with the 
exception that serum control wells received 50 ul of MEM only. The 
plates were gently shaken and incubated for one hour at 37 C in a 5% co2 
humidified incubator. Following incubation, 50 ul of MEM containing 
approximately 105•6 MDBK cells were added to each well and the plates 
reincubated for 48 hours. Serum-virus neutralizing titers were expressed 
as the reciprocal of the highest dilution that produced complete 
neutralization of virus (log2). 
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Production of Immune Serum 
Immune serum pools were made from unvaccinated control pigs from 
previous studies that survived intranasal virus challenge of 107•3 PFU of 
PRY. Normal serum was collected from pigs prior to the virus challenge. 
Early and late immune serums were collected 7 and 21 days post-virus 
challenge (pc) / respectively. Normal serum and early immune serum pools 
were negative for SN antibody. The SN antibody titer of the late immune 
serum pool was 3.0 log2• 
Subunit Vaccine Preparation 
Pseudorabies virus glycoproteins were prepared as described by 
Platt, 13 ·quantitated by the dye binding method of Bradford3 and used as 
subunit vaccine. The experimental regime consisted of two doses of 
vaccine. The first dose consisted of 100 ug of non-adjuvanted viral 
glycoproteins combined with five ml of normal serum, or early or late 
immune serum. The antigen-immune serum mixtures were incubated at 37 c 
for one hour to facilitate the formation of inimune complexes. The second 
dose consisted of the 100 ug of non-adjuvanted viral glycoproteins alone. 
Experimental Design 
Eighteen weanling pigs were randomly divided into three treatment 
groups of five pigs each and an uninoculated control group of three pigs. 
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All treated pigs were inoculated subcutaneously with an initial dose of 
antigen combined with normal, early immune, or late immune serum. A 
second dose of antigen without serum was given 14 days later. All pigs 
were nasally challenged with 107•3 PFU of virus 21 days after the second 
antigen dose. 
The effect of serum treatment was evaluated by comparing the mean SN 
antibody response of the treated groups during the immunization period, 
and following virus challenge. The survival rates of the three 
treatments were compared after virus challenge. Data was analyzed by an 
analysis of variance procedure (ANOVA) using a randomized complete block 
design. 18 The data was blocked by day in the ANOVA procedure to control 
the day to day variability in the test results. Survival rates were 
compared by chi-square analysis •. 18 
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RESULTS 
The mean SN 'antibody titers of the treatments are summarized in 
Table 1. No SN antibody was detected in any pig prior to day 7 pc. On 
day 7 pc, the mean SN antibody titers were 3.00 +0.82, 3.00 +0.71, and 
1.40 +0.24 log2 for the normal, early immune, and late immune serum 
treatments, respectively. The SN antibody titer of· the late immune serum 
treatment was significantly less (p<0.01) than the normal and early 
immune serum treatments. All SN antibody titers of the treatment groups 
were essentially equal beyond day 7 pc. Unvaccinated control pigs 
remained free of SN antibody until day 7 pc when all surviving pigs had 
titers of 1.00 +0.00 log2• By day 10 pc, the mean SN antibody titer rose 
to 2.5 + 0.50 log2 which was markedly less than the titers of the 
vaccinated treatments. The absence of a SN antibody response in the 
unvaccinated control pigs prior to virus challenge, and the absence of an 
anamnestic response pc indicates that all the pigs were free of PRV until 
challenged. 
The survival rates of the three treatment groups, that received the 
PRV subunit vaccine with normal, early immune, and late immune serum, 
were 2 of 5 (40%), 5 of 5 (100%), and 4 of 5 (80%) pigs, respectively. 
The survival rate of the unvaccinated control treatment was 2 of 3 (67%) 
pigs. Clinical disease appeared to be more severe in unvaccinated 
control and normal immune serum treated pigs than in early and late 
immune sera treated pigs. All death losses in the first two groups 
occurred between days 4 and 8 pc. In contrast, the one death among pigs 
treated with late· immune serum occurred on day 10 pc. 
Table 1. The effect of pseudorabies inunune serum on the serum-virus neutralizing antibody response 
of pigs inununized with a non-adjuvanted pseudorabies virus subunit vaccine 
Mean seru~virus neutralizing antibody titer + SE (log2) by daya 
Treatmentb NC -35 -21 -14 -11 -7 0 4 7 10 14 21 
Normal serum 5 0.00 0.00 0.80 0.20 o.oo 0.00 o.oo 3.00 4.00 4.50 4.50 
+o.oo +o.00 +0.05 +0.20 +0.00 +0.00 +o.oo +0.82 +0.00 +1.00 +1.00 
Early serum 5 0.00 o.oo 0.40 o.oo 0.00 0.00 0.00 3.00 4.10 4.80 4.60 
+0.00 +o.oo +0.24 +0.00 +0.00 +0.00 +o.oo +0.71 +0.37 +0.41 +0.19 
Late serum 5 o.oo 0.00 o.oo 0.00 o.oo ** 0.00 o.oo 1.40 4.30 4.88 5.13 
+o.oo +o.oo +0.00 +0.00 +o.oo +0.00 +o.oo +0.24 +0.20 +0.13 +0.13 
Unvaccinated 3 o.oo 0.00 0.00 o.oo o.oo 0.00 o.oo 1.00 2.50 4.25 4.00 
control +0.00 +o.oo +0.00 +0.00 +0.00 +o.oo +0.00 +0.00 +0.50 +o.25 +o.oo 
a Day 0 is the day of virus challenge. 
bNormal serum = serum collected prior to virus challenge + vaccine; Early serum = serum 
collected on day 7 pc + vaccine; Late serum = serum collected on day 21 pc +vaccine; 
Unvaccinated control = no serum or vaccine. 
cN equals total number of pigs at start of experiment. N = 2 on days 7 through 21 pc for the 
unvaccinated control and normal serum treatments. N = 4 for the late serum treatment on days 
14 and 21 pc. 
** p<0.01. 
"' ID 
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DISCl.JSSION 
The primary objective of this experiment was to determine if the 
incorporation of PRV immune serum with a PRV subunit vaccine would 
enhance the immune response of pigs to the vaccine. The results of this 
limited study indicate that PRV immune serum did not markedly enhanced 
the immune response. However, the SN antibody response and survival rate 
of pigs receiving early immune serum suggest that some enhancement of the 
immune response may have occurred. All five (100%) pigs that received 
early immune serum with vaccine survived the virus challenge, while only 
2 of 5 (40%) pigs receiving normal immune serum with the vaccine 
survived. The data also indicate that the immune response of pigs which 
received the late immune serum may have been slightly suppressed as 
indicated by the SN antibody response. On day 7 pc, the mean SN antibody 
titer of pigs treated with late immune serum was 1.60 log 2 less than the 
mean SN antibody titers of pigs treated with either normal or early 
immune serum (p<0.01). 
These results were not unexpected assuming that IgM and IgG were the 
immunomodulating components of the early and late immune sera, 
respectively.. Several investigators have documented that IgM can enhance 
the SN antibody response to a specific antigen if the immunoglobulin is 
presented to the host before or concurrently with the antigen.5' 7, 10 
The immunosuppressive effect of IgG, when given prior to or concurrently 
with antigen has also been documented.7 
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It is recognized that these conclusions are statistically weak due 
to the small number of pigs involved in this study. Another deficiency 
of the study was the lack of knowledge of whether or not the antigen or 
the antibody was in excess in the inoculum. The ratio of antigen to 
antibody has been demonstrated to affect the outco~ on the immune 
response. 1 Insufficient antibody may not affect the immune response, 
while excessive antibody may actually depress the immune response. Also, 
high levels of IgM may actually suppress the SN antibody response, 11 
although the levels of IgM in the preparations were insignificant 
compared .to the dilution achieved in the pigs. Other components of the 
immune serum may actually have been responsible for the observed effects 
of the treatments. 21 Additional experimentation will be required in 
order to determine whether or not immune serum can be used as an 
economical and efficient immunopotentiating agent. 
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SUMMARY 
Two lectins, Concanavalin A (ConA) and Lens culinaris agglutinin 
(LCA), and pseudorabies early and late immune sera were evaluated for 
their effect on the porcine immune response to a pseudorabies subunit 
vaccine. The viral glycoproteins of the subunit vaccine are expensive to 
produce relative to attenuated and inactivated vaccines. The cost of the 
subunit vaccine could be reduced if a way of enhancing the porcine immune 
response to the viral glycoproteins was developed. A reduction in the 
dose of antigen required for the subunit vaccine to induce a protective 
immune response to PRV would subsequently reduce the cost of the vaccine. 
The lectins and immune sera did not enhance the porcine immune response 
to the pseudorabies subunit vaccine. In fact, the ConA and late immune 
serum treatments ,appeared to suppress the porcine immune response. 
However, the early immune serum appeared to confer a degree of 
protection, although that experiment was only a preliminary study. 
The 150 ug of lectin, ConA or LCA, were incorporated into the 
pseudorabies subunit vaccine, containing 15 ug of viral glycoproteins, in 
the presence and absence of Freund's incomplete adjuvant. Mean serum-
virus neutralizing (SN) antibody, cell-mediated immunity (CM!) and the 
clinical response of the pigs post-virus challenge (pc) were used to 
evaluate the different treatments. The LCA had no observable effect on 
the SN antibody or CM!, while the ConA appeared to reduce the SN antibody 
prior to day 7 pc and the post-challenge CMI. The mean SN antibody 
titers, on day 7 pc, were 4.62 :!:. 0.42, 4.00 :!:. 0.35, and 3.11 :!:. 0.28 log
2 
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for the adjuvanted lectin-free, LCA, and ConA treatments,· respectively. 
A similiar trend was observed in the non-adjuvanted study. The overall 
mean virus stimulation indexes for the post-challenge CMI were 2.77, 
2.65 1 and 1.91 for the lectin-free, LCA, and ConA treatments, 
respectively. A stimulation index greater than 2.0 is considered to be a 
positive CMI. The CMI was not measured in the non-adjuvanted study. 
The clinical response of the pigs yielded further evidence that the 
lectins may have reduced the porcine immune response. This effect was 
most apparent between days 4 and 8 pc, when the symptoms of the disease 
were most severe. The mean daily weight gains for this period were 0.440 
+ 0.097, 0.298 + 0.162, 0.297 .:!:. 0.035 Kg-day-1 for the adjuvanted lectin-
free, LCA, and ConA treatments, respectively. In addition, the ConA 
treatment consistently shed virus 48 hours longer and in larger 
quantities than the lectin-free or LCA treatments. 
The five ml of pseudorabies immune sera, normal, early, or late, 
were incorporated into the pseud0rabies subunit vaccine, containing 100 
ug of viral glycoproteins, in the absence of adjuvant. The normal and 
early immune sera were seronegative for SN antibody to PRV, while the 
late immune serum was seropositive with a SN antibody titer of 3.0 log
2
• 
Mean SN antibody and survival of the virus challenge were used to 
evaluate the treatments. Normal and early immune sera had no apparent 
enhancing effect on the SN antibody response of the pigs to the 
pseudorabies subunit vaccine, while late immune serum appeared to 
suppress the SN antibody response pc. The SN antibody titers on day 7 pc 
were 3.00 +0.82, 3.00 +0.71, and 1.40 +0.24 log for the normal early - - - 2 I I 
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and late serum treatments, respectively. However, of the· five pigs that 
started the experiment in each treatment, only two of the normal, and 
four of the late immune serum treated pigs survived the virus challenge 
as compared to 100% survival of the early immune serum treated pigs. The 
small nunber of pigs involved in the immune serum study requires that 
additional experimentation be performed to determine whether or not 
inmune serum can be used as an economical and efficient 
immunopotentiating agent of the PRV subunit vaccine. 
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